SCHEMBL4511968

SCHEMBL4511968

C[C@@H](N)CNc1nc(-c2ccc(O)cc2O)nc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.52
MEN1 O00255 9/20 0.52
KMT2A Q03164 9/20 0.52
RXFP1 Q9HBX9 1/20 0.52
MAPT P10636 7/20 0.50
GAA P10253 3/20 0.49
POLB P06746 2/20 0.49
NTRK1 P04629 1/20 0.49
ALK Q9UM73 1/20 0.49
PIP4K2A P48426 1/20 0.47
HIF1A Q16665 2/20 0.47
NPSR1 Q6W5P4 2/20 0.46
EGFR P00533 2/20 0.46
PKM P14618 1/20 0.46
GPR35 Q9HC97 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
PRKCI P41743 2/20 0.43
LMNA P02545 2/20 0.43
HCRTR1 O43613 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4511979 1.00 ACP1 (0.52) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL4522060 0.92 ACP1 (0.51) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL4522067 0.92 ACP1 (0.51) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL4504137 0.90 ACP1 (0.52) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL4504126 0.90 ACP1 (0.52) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL4504133 0.90 ACP1 (0.52) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL4509435 0.90 ACP1 (0.51) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL4509430 0.90 ACP1 (0.51) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL3907257 0.89 MEN1 (0.65) ACP1MEN1KMT2ARXFP1MAPT
SCHEMBL4501723 0.89 MEN1 (0.65) ACP1MEN1KMT2ARXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
WO-2007125331-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE PKD2, PKD1, AADAT ACP1 282/4885MEN1 4237/4885KMT2A 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.